Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 13 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

8%

1 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

6 recruiting

Enrollment Performance

Analytics

N/A
8(61.5%)
Phase 1
4(30.8%)
Phase 3
1(7.7%)
13Total
N/A(8)
Phase 1(4)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (13)

Showing 13 of 13 trials
NCT07343986Phase 1Recruiting

Study of Low-Intensity Focused Ultrasound in Combination With Immunotherapy in Newly Diagnosed Unmethylated Glioblastoma

Role: collaborator

NCT04988750Not ApplicableCompleted

Evaluate the Safety and Preliminary Efficacy of the Combination of NaviFUS System With Re-irradiation for rGBM Patients

Role: lead

NCT06496971Phase 3Recruiting

A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients

Role: lead

NCT06388707Phase 1Recruiting

A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy

Role: lead

NCT04999046Not ApplicableCompleted

NaviFUS™ System Neuromodulating Treatment for Patients With Drug Resistant Epilepsy

Role: lead

NCT06492720Not ApplicableRecruiting

A Pilot Study to Evaluate the Efficacy and Safety of NaviFUS™ System Neuromodulating Treatment for Patients With Drug Resistant Epilepsy

Role: lead

NCT06329570Phase 1Recruiting

Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)

Role: lead

NCT04446416Not ApplicableCompleted

Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients

Role: lead

NCT07385846Phase 1Not Yet Recruiting

Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair Deficiency

Role: collaborator

NCT07274787Not ApplicableNot Yet Recruiting

Safety And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent Glioblastoma

Role: collaborator

NCT05947656Not ApplicableRecruiting

Evaluation of the NaviFUS System in Drug Resistant Epilepsy

Role: collaborator

NCT03860298Not ApplicableCompleted

Safety of Using NaviFUS System in Patients With Drug Resistant Epilepsy

Role: lead

NCT03626896Not ApplicableCompleted

Safety of BBB Disruption Using NaviFUS System in Recurrent Glioblastoma Multiforme (GBM) Patients

Role: lead

All 13 trials loaded